Debiopharm S.A.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear

The number of venture capital mega-rounds raised by biopharmaceutical companies has settled into a steady pace of six $100m-plus financings per month, with May matching the number of supersized VC rou

The market for targeted radiotherapy in oncology could soon become a bit more competitive as ITM Isotope Technologies Munich unveiled topline Phase III results for ITM-11 (non-carrier-added 177 Lu-edo

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre